Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 11Phase 1/2 6Phase NA 2Phase 2/3 2Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Graft vs Host Disease 1

Interventions

Azacitidine 2siltuximab 1pembrolizumab 1nilotinib 1ioversol 1interferon gamma-1b 1fludarabine phosphate 1fluarix 1daratumumab 1Whole-Body Irradiation 1Watchful Waiting 1Transplantation 1Stem Cell Transplantation 1Pleurodesis 1Photopheresis 1Pemetrexed 1Observation 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Mycophenolic Acid 1Mesenchymal Stem Cell Transplantation 1Injections 1Influenza Vaccines 1Imatinib Mesylate 1Hyperbaric Oxygenation 1Fluzone High-Dose 1FluLaval 1FluBlok 1Decitabine 1Cyclosporine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Injections × Myeloid × Clear all
NCT04628338 2025-04-29

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

University of Pittsburgh

Phase EARLY_PHASE1 Completed
8 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myeloid, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡